title: Intraluminal Flagellin Differentially Contributes to Gut Dysbiosis and Systemic Inflammation following Burn Injury.
abstract: Burn injury is associated with a loss of gut barrier function, resulting in systemic dissemination of gut-derived bacteria and their products. The bacterial protein and TLR5 agonist, flagellin, induces non-specific innate immune responses. Because we detected flagellin in the serum of burn patients, we investigated whether gut-derived flagellin was a primary or secondary contributor to intestinal dysfunction and systemic inflammation following burn injury. The apical surface of polarized human intestinal epithelial cells (IECs), Caco-2BBe, were exposed to 50 or 500 ng of purified flagellin and 1 x 105 of an intestinal E. coli (EC) isolate as follows: 1) flagellin added 30 min prior to EC, 2) flagellin and EC added simultaneously, or 3) EC added 30 min prior to flagellin. Our results showed that luminal flagellin and EC modulated each other's biological actions, which influenced their ability to induce basolateral secretion of inflammatory cytokines and subsequent translocation of bacteria and their products. A low dose of flagellin accompanied by an enteric EC in the lumen, tempered inflammation in a dose- and time-dependent manner. However, higher doses of flagellin acted synergistically with EC to induce both intestinal and systemic inflammation that compromised barrier integrity, increasing systemic inflammation following burn injury, a process we have termed flagellemia. In a murine model of burn injury we found that oral gavage of flagellin (1 μg/mouse) significantly affected the gut microbiome after burn injury. In these mice, flagellin disseminated out of the intestine into the serum and to distal organs (mesenteric lymph nodes and lungs) where it induced secretion of monocyte chemoattractant protein (MCP-1) and CXCL1/KC (mouse equivalent of human IL-8) at 24 and 48h post-burn. Our results illustrated that gut-derived flagellin alone or accompanied by a non-pathogenic enteric EC strain can function as an initiator of luminal and systemic inflammation following burn injury.
authors.affiliation: Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Logan
authors.initials: L
authors.lastname: Grimes
authors.affiliation: Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Allie
authors.initials: A
authors.lastname: Doyle
authors.affiliation: Pediatrics, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Aaron L
authors.initials: AL
authors.lastname: Miller
authors.affiliation: Pediatrics, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Pyles
authors.affiliation: Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Gabor
authors.initials: G
authors.lastname: Olah
authors.affiliation: Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.|Shriners Hospitals for Children, Galveston, Texas, United States of America.
authors.forename: Csaba
authors.initials: C
authors.lastname: Szabo
authors.affiliation: Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
authors.forename: Sarah
authors.initials: S
authors.lastname: Hoskins
authors.affiliation: Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.|Shriners Hospitals for Children, Galveston, Texas, United States of America.
authors.forename: Tonyia
authors.initials: T
authors.lastname: Eaves-Pyles
mesh_terms: D000818:Animals; D002056:Burns / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D018932:Chemokine CCL2 / Q000378:metabolism; D054360:Chemokine CXCL1 / Q000378:metabolism; D064806:Dysbiosis / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D004926:Escherichia coli / Q000472:pathogenicity; D005408:Flagellin / Q000008:administration & dosage / Q000378:metabolism*; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007249:Inflammation / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology / Q000473:pathology; D051379:Mice
chemical_list: C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D054360:Chemokine CXCL1; C475895:Cxcl1 protein, mouse; D005408:Flagellin